-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Click on the blue text above to follow us Ronald Swanstrom and Raymond Schinazi propose in a Perspective that antiviral strategies that allow RNA viruses to produce genetic mutations so fast that the virus cannot remove those harmful mutations are used in With the recently approved COVID-19 treatment molnupiravir, this strategy may work, but it could also pose unknown risks to the host
.
The authors say the safety of mutagenic drugs needs to be more carefully scrutinized due to possible long-term effects, including the possibility of variants and possible mutation of host DNA
.
Lethal mutagenesis is an antiviral strategy in which drugs form mutagenic ribonucleosides for viral RNA replication in host cells, thereby introducing errors in the virus' genetic code to prevent further replication, ultimately leading to invading viruses perish
.
Several mutagenic drugs have been developed using this approach, including the antiviral drug monubiravir, which is effective against SARS-CoV-2
.
However, according to the authors, knowledge gaps exist between short-term laboratory-based detection of mutagenic activity and long-term risks to human health, including those associated with cancer or reproduction, that may take years to become apparent
.
Swanstrom and Schinazi discuss these risks and how to assess them
.
They made recommendations on how to proceed with treatment with lethal mutagenic drugs
.
Swanstrom and Schinazi write: "Lethal mutagenesis has the potential to be an important antiviral strategy against RNA viruses, especially in viral infections in the absence of specific antiviral drugs
.
The potential of this strategy should be exploited, but it should also be recognized and Solve its possible risks
.
" Welcome to pay attention to Science's official public account and click "Read the original text" below to access the English original text for this issue of Science to light up your reading!
.
The authors say the safety of mutagenic drugs needs to be more carefully scrutinized due to possible long-term effects, including the possibility of variants and possible mutation of host DNA
.
Lethal mutagenesis is an antiviral strategy in which drugs form mutagenic ribonucleosides for viral RNA replication in host cells, thereby introducing errors in the virus' genetic code to prevent further replication, ultimately leading to invading viruses perish
.
Several mutagenic drugs have been developed using this approach, including the antiviral drug monubiravir, which is effective against SARS-CoV-2
.
However, according to the authors, knowledge gaps exist between short-term laboratory-based detection of mutagenic activity and long-term risks to human health, including those associated with cancer or reproduction, that may take years to become apparent
.
Swanstrom and Schinazi discuss these risks and how to assess them
.
They made recommendations on how to proceed with treatment with lethal mutagenic drugs
.
Swanstrom and Schinazi write: "Lethal mutagenesis has the potential to be an important antiviral strategy against RNA viruses, especially in viral infections in the absence of specific antiviral drugs
.
The potential of this strategy should be exploited, but it should also be recognized and Solve its possible risks
.
" Welcome to pay attention to Science's official public account and click "Read the original text" below to access the English original text for this issue of Science to light up your reading!
